Dan Leonard, president and CEO of the National Pharmaceutical Council (NPC), discussed in a recent article published on Specialty Pharmacy Times the council’s comments on the Health and Human Service’s request for comment on its drug-pricing blueprint.
The council, he writes, said drug pricing solutions “must be grounded in strong evidence and analysis” that pays mind to the complexity of health spending.
“In our comments, we also highlighted value assessment, an area that is still evolving in this country as diverse organizations wrestle over frameworks and approaches,” Leonard writes. “Our work at NPC has focused on ensuring that value assessments follow sound methodological practices to ensure that they are effective tools to support value in patient care and outcomes and are not barriers to treatments.”
To read Leonard’s full article on Specialty Pharmacy Times, click here.
